CrestPoint Capital Management’s Idexx Laboratories IDXX Stock Holding History

CrestPoint Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3,400	Closed	-$252K	–	235
2014 Q4	$252K	Hold	3,400	–	–	0.14%	200
2014 Q3	$200K	Hold	3,400	–	–	0.12%	210
2014 Q2	$227K	Hold	3,400	–	–	0.13%	197
2014 Q1	$206K	Buy	+3,400	New	+$203K	0.13%	208

Other funds holding IDXX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCG

Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CrestPoint Capital Management's IDXX Position: Q1 2015 in Review

CrestPoint Capital Management sold out of Idexx Laboratories (IDXX) in Q1 2015, closing a stake of 3,400 shares — an estimated $252K sold.

CrestPoint Capital Management first reported a position in IDXX in Q1 2014 and held it in 4 quarters. The position peaked at $252K in Q4 2014. 344 funds tracked by Wall St. Rank hold IDXX as of Q1 2015.

CrestPoint Capital Management reported no remaining Idexx Laboratories position as of Q1 2015 after selling out during the quarter.
CrestPoint Capital Management sold 3,400 Idexx Laboratories shares in Q1 2015, an estimated $252K.
CrestPoint Capital Management first reported a position in Idexx Laboratories in Q1 2014 and held it in 4 quarters.
CrestPoint Capital Management's Idexx Laboratories position peaked at $252K in Q4 2014.
344 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2015.

Based on CrestPoint Capital Management's 13F filing for Q1 2015, filed 14 Apr 2015.